Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.55), $0.17 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $30.48 million versus the consensus estimate of $20.02 million.

GUIDANCE:

Acadia Pharma sees FY2017 revenue of $105-115 million.

“Our commercial efforts continue to drive strong financial performance with solid market uptake for NUPLAZID in patients with Parkinson’s disease psychosis,” said Steve Davis, ACADIA’s President and Chief Executive Officer. “Following positive data from our Phase II study in Alzheimer’s disease psychosis and recently completed End-of-Phase II meeting with the FDA, we are excited to start our Phase III program in the next couple of months.”

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.